分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

L ARP7 Is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis

Fang Zhang, Pengyi Yan, Huijing Yu, Huangying Le, Zixuan Li, Jiahuan Chen, Xiaodong Liang, Shiyan Wang, Weiting Wei, Li Liu, Yan Zhang, Xing Ji, Anyong Xie, Wantao Chen, Zeguang Han, William T. Pu, Sun Chen, Yingwei Chen, Kun Sun, Baoxue Ge, Bing Zhang

Journal:Cell Reports

IF:8.11

DOI:10.1016/j.celrep.2020.107974

PMID:32726637

Published:2020-07-28

research field:分子生物学细胞生物学癌症生物学遗传学

Abstract

Summary Attenuated DNA repair leads to genomic instability and tumorigenesis. BRCA1/BARD1 are the best-known tumor suppressors that promote homology recombination (HR) and arrest cell cycle. However, it remains ambiguous whether and how their E3 ligase activity regulates HR. Here, we demonstrate that upon genotoxic stress, BRCA1 together with BARD1 catalyzes the K48 polyubiquitination on LARP7, a 7SK RNA binding protein known to control RNAPII pausing, and thereby degrades it through the 26S ubiquitin-proteasome pathway. Depleting LARP7 suppresses the expression of CDK1 complex, arrests the cell at the G2/M DNA damage checkpoint, and reduces BRCA2 phosphorylation, which thereby facilitates RAD51 recruitment to damaged DNA to enhance HR. Importantly, LARP7 depletion observed in breast cancer patients leads to chemoradiotherapy resistance both in vitro and in vivo. Altogether, this study unveils a mechanism by which BRCA1/BARD1 control HR and cell cycle, and highlights LARP7 as a potential target for cancer prevention and therapy.

本文使用的Yeasen产品

购物车
客服
转染试用